Cargando…
Influence of menopause on chemotherapy‐induced nausea and vomiting in highly emetogenic chemotherapy for breast cancer: A retrospective observational study
BACKGROUND: Female sex and younger age are reported risk factors for chemotherapy‐induced nausea and vomiting (CINV) in highly emetogenic chemotherapy, but the underlying mechanism has not been elucidated. The purpose of this study was to clarify the impact of menopause on CINV. METHODS: This retros...
Autores principales: | Yokokawa, Takashi, Suzuki, Kenichi, Tsuji, Daiki, Hosonaga, Mari, Kobayashi, Kazuo, Kawakami, Kazuyoshi, Kawazoe, Hitoshi, Nakamura, Tomonori, Suzuki, Wataru, Sugisaki, Takahito, Aoyama, Takeshi, Hashimoto, Koki, Hatori, Masahiro, Tomomatsu, Takuya, Inoue, Ayaka, Azuma, Keiichi, Asano, Maimi, Takano, Toshimi, Ohno, Shinji, Yamaguchi, Masakazu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557896/ https://www.ncbi.nlm.nih.gov/pubmed/37676079 http://dx.doi.org/10.1002/cam4.6494 |
Ejemplares similares
-
Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
por: Escobar, Yolanda, et al.
Publicado: (2015) -
The Effect and Safety of Olanzapine on Nausea and Vomiting in Children Receiving Moderately Emetogenic Chemotherapy
por: Eghbali, Aziz, et al.
Publicado: (2023) -
Erratum to: Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
por: Escobar, Yolanda, et al.
Publicado: (2015) -
Open-label observational study to assess the efficacy and safety of aprepitant for chemotherapy-induced nausea and vomiting prophylaxis in Indian patients receiving chemotherapy with highly emetogenic chemotherapy/moderately emetogenic chemotherapy regimens
por: Hingmire, Sachin, et al.
Publicado: (2015) -
Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy
por: Gao, Ai, et al.
Publicado: (2023)